Hepatitis C virus inhibitors

A compound of formula (I)

• or a pharmaceutically acceptable salt thereof, wherein
• R1 is selected from hydroxy and —NHSO2R5;
• R2 is selected from hydrogen, alkenyl, alkyl, and cycloalkyl, wherein the alkenyl, the alkyl, and the cycloalkyl are each optionally substituted with one, two, three, or four halo groups;
• R3 is a phenyl group substituted with an additional phenyl or a heterocyclyl wherein the additional phenyl and the heterocyclyl can be further optionally substituted with one, two, three, four, or five substituents independently selected from alkoxy, alkyl, cyano, halo, haloalkoxy, haloalkyl, and hydroxy;
• R4 is selected from hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylsulfonyl, cycloalkyloxycarbonyl, haloalkoxycarbonyl, haloalkyl, haloalkylcarbonyl, haloalkylsulfonyl, (NRaRb)carbonyl, and (NRaRb)sulfonyl, wherein the cycloalkyl part of the cycloalkyloxycarbonyl is optionally substituted with one, two, or three haloalkyl groups;
• R5 is selected from alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, heterocyclyl, and —NRaRb;
• wherein the alkyl and cycloalkyl are each optionally substituted with one group selected from alkyl, alkoxy, halo, haloalkyl, cyano, cyanoalkyl, and haloalkoxy;
• Ra and Rb are independently selected from hydrogen, alkoxy, alkyl, aryl, arylalkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, heterocyclyl, and heterocyclylalkyl;
• X is selected from O, S, SO, and SO2;
• and
• Q is a C5-9 saturated or unsaturated chain optionally substituted with one or two groups independently selected from alkyl, halo, and haloalkyl.